welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
NIH Awards $86 Million to Improve Genome Editing Techniques
Somatic Cell Genome Editing support is aimed at improving therapeutic options for both rare and common diseases.
Making changes to a patients DNA can have powerful implications for the treatment of disease. To tap into this immense potential, NIH recently awarded 21 Somatic Cell Genome Editing grants — totaling approximately $86 million over the next five years, pending available funds — to support research aimed at improving methods to edit the human genome. These grants are the first to be awarded through the Somatic Cell Genome Editing (SCGE) program, which was launched in January 2018 with NIH Common Fund support. As a trans-NIH endeavor, SCGE is managed by staff from multiple NIH Institutes and Centers, with leadership from NCATS.
rareRelated
-
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...
-
Nutrition Considerations in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a s...
-
Parent Project Muscular DystrophyParent Project Muscular Dystrophy (PPMD)...
-
BIOPHYTIS receives orphan drug designation in the United States for Sarconeos in Duchenne muscular dystrophy (DMD)BIOPHYTIS, a biotechnology company speci...
-
Regular Physical Exercise in Duchenne Muscular DystrophyThis study examine whether an evidence-b...
-
The emerging role of viral vectors as vehicles for DMD gene editingDuchenne muscular dystrophy (DMD) is a g...
-
Hope for Gabe (H4G)Hope for Gabe Foundation was created in ...
